Len De Nys
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Len De Nys has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Nele Adriaenssens
Rehabilitation Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium
5 shared publications - Amy de Haar-Holleman
Department of Medical Oncology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
3 shared publications - David Beckwée
Vrije Universiteit Brussel
3 shared publications - Katrien Lanckmans
Department of Clinical Biology, Universitair Ziekenhuis Brussel, Brussels, Belgium
3 shared publications - Pieter-Jan De Sutter
Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
3 shared publications - Sofie Vande Casteele
Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Universiteit Gent, Ottergemsesteenweg 460, 9000 Gent, Belgium
3 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Research Square
Associations of body composition and physical activity with treatment burden during weekly paclitaxel for breast cancer: an exploratory prospective cohort study
Purpose To characterise treatment burden regarding adverse events, relative dose intensity and treatment modifications and their associations with body composition, physical activity, and paclitaxel exposure in breast cancer patients. Methods This prospective cohort included 20 women with breast cancer receiving 12 cycles of weekly paclitaxel. Body composition was assessed by computed tomography, dual-energy X-ray absorptiometry, and bioelectrical impedance; physical activity by accelerometry. Patient-reported outcomes, medical-record adverse events, relative dose intensity, treatment modifications and paclitaxel concentrations were documented. Baseline-adjusted mixed-effects models examined body composition and physical activity markers. Results From baseline to final follow-up, sensory neuropathy and fatigue increased by 10.0, 95% CI [4.8, 15.1] and 19.4 points, 95% CI [9.5, 29.3], while physical functioning and global health declined by 10.4, 95% CI [2.8, 18.0] and 10.7 points, 95% CI [1.5–19.8]. No adverse event reached Common Terminology Criteria for Adverse Events grade ≥ 3; yet 65% of participants had a toxicity-attributed treatment modification. Higher adiposity markers across imaging modalities and body mass index were associated with worse sensory neuropathy. Per 1,000 additional steps/day, fatigue was 4.54 points lower, 95% CI [− 8.42, − 0.66], physical functioning 1.92 higher, 95% CI [0.23, 3.61], and global health 2.48 higher, 95% CI [0.33, 4.63]. No consistent associations were observed with relative dose intensity, modification count, or adverse-event burden. Conclusion Weekly paclitaxel was accompanied by clinically important patient-reported deterioration and frequent treatment modifications despite no CTCAE grade ≥ 3 events. Greater adiposity and lower physical activity were associated with higher patient-reported burden; the design does not support causal or clinical inference. Trial registration ClinicalTrials.gov NCT06387901, registered 29 April 2024.
- 6 October 2026
- Published by Springer Nature in Research Square
Open AccessAssociations of body composition and physical activity with treatment burden during weekly paclitaxel for breast cancer: an exploratory prospective cohort study
Purpose To characterise treatment burden regarding adverse events, relative dose intensity and treatment modifications and their associations with body composition, physical activity, and paclitaxel exposure in breast cancer patients. Methods This prospective cohort included 20 women with breast cancer receiving 12 cycles of weekly paclitaxel. Body composition was assessed by computed tomography, dual-energy X-ray absorptiometry, and bioelectrical impedance; physical activity by accelerometry. Patient-reported outcomes, medical-record adverse events, relative dose intensity, treatment modifications and paclitaxel concentrations were documented. Baseline-adjusted mixed-effects models examined body composition and physical activity markers. Results From baseline to final follow-up, sensory neuropathy and fatigue increased by 10.0, 95% CI [4.8, 15.1] and 19.4 points, 95% CI [9.5, 29.3], while physical functioning and global health declined by 10.4, 95% CI [2.8, 18.0] and 10.7 points, 95% CI [1.5–19.8]. No adverse event reached Common Terminology Criteria for Adverse Events grade ≥ 3; yet 65% of participants had a toxicity-attributed treatment modification. Higher adiposity markers across imaging modalities and body mass index were associated with worse sensory neuropathy. Per 1,000 additional steps/day, fatigue was 4.54 points lower, 95% CI [− 8.42, − 0.66], physical functioning 1.92 higher, 95% CI [0.23, 3.61], and global health 2.48 higher, 95% CI [0.33, 4.63]. No consistent associations were observed with relative dose intensity, modification count, or adverse-event burden. Conclusion Weekly paclitaxel was accompanied by clinically important patient-reported deterioration and frequent treatment modifications despite no CTCAE grade ≥ 3 events. Greater adiposity and lower physical activity were associated with higher patient-reported burden; the design does not support causal or clinical inference. Trial registration ClinicalTrials.gov NCT06387901, registered 29 April 2024.
- 7 February 2026
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- p. 1-12
Body composition and physical activity as predictors of immune-related adverse events in patients undergoing cancer immunotherapy: a systematic review
Host factors may affect immune-related adverse events (irAE) during immune checkpoint inhibitor (ICI) therapy. We systematically reviewed studies on body composition (BMI, CT/DXA-defined sarcopenia, sarcopenic obesity) and physical activity (PA) in relation to irAE incidence and severity in ICI-treated adults. PubMed, Embase, Scopus, and Web of Science were searched from inception to 15 December 2024. Eligible studies assessed baseline body composition and/or PA in relation to irAE. Risk of bias was evaluated using the NIH tool and QUIPS. Findings were synthesized using structured narrative methods. Seven studies (2,590 patients) were included. Two large cohorts found overweight/obese patients had higher odds of any-grade irAE (OR = 1.4-1.5); one disease-specific cohort found no association. One CT-based study showed higher irAE risk with sarcopenia (OR = 2.64) and more with sarcopenic obesity (OR = 5.50). Two studies on PA were conflicting: one found higher PA reduced severe irAE risk (OR = 0.19), another found no association. Body composition and PA may help predict irAE in ICI-treated patients. Evidence is low to very low certainty: overweight/obesity may increase toxicity risk, higher PA may lower risk, and evidence for sarcopenia is limited. Standardized prospective studies are needed to confirm these associations. : https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251084119.
- 7 February 2026
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- p. 1-12
Body composition and physical activity as predictors of immune-related adverse events in patients undergoing cancer immunotherapy: a systematic review
Host factors may affect immune-related adverse events (irAE) during immune checkpoint inhibitor (ICI) therapy. We systematically reviewed studies on body composition (BMI, CT/DXA-defined sarcopenia, sarcopenic obesity) and physical activity (PA) in relation to irAE incidence and severity in ICI-treated adults. PubMed, Embase, Scopus, and Web of Science were searched from inception to 15 December 2024. Eligible studies assessed baseline body composition and/or PA in relation to irAE. Risk of bias was evaluated using the NIH tool and QUIPS. Findings were synthesized using structured narrative methods. Seven studies (2,590 patients) were included. Two large cohorts found overweight/obese patients had higher odds of any-grade irAE (OR = 1.4-1.5); one disease-specific cohort found no association. One CT-based study showed higher irAE risk with sarcopenia (OR = 2.64) and more with sarcopenic obesity (OR = 5.50). Two studies on PA were conflicting: one found higher PA reduced severe irAE risk (OR = 0.19), another found no association. Body composition and PA may help predict irAE in ICI-treated patients. Evidence is low to very low certainty: overweight/obesity may increase toxicity risk, higher PA may lower risk, and evidence for sarcopenia is limited. Standardized prospective studies are needed to confirm these associations. : https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251084119.
- 24 January 2026
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 17 (2) , 102854
A literature review on hypothalamic–pituitary–adrenal (HPA) axis dysregulation in older adults with cancer: A missing link in predicting treatment toxicity?
- 24 January 2026
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 17 (2) , 102854
A literature review on hypothalamic–pituitary–adrenal (HPA) axis dysregulation in older adults with cancer: A missing link in predicting treatment toxicity?
- Open Access
- 8 January 2026
- Published by MDPI AG in Preprints.org
A Literature Review on Hypothalamic–Pituitary–Adrenal (HPA) Axis Dysregulation in Older Adults with Cancer: A Missing Link in Predicting Treatment Toxicity?
Older adults with cancer face disproportionately high rates of severe treatment-related toxicities, yet current prediction tools rarely incorporate biomarkers that capture physiological resilience. The hypothalamic–pituitary–adrenal (HPA) axis—central to stress adaptation, immune regulation, and tissue repair—undergoes pronounced age-related alterations, including elevated basal cortisol, reduced dehydroepiandrosterone (DHEA) and its sulphate form DHEAS, and an increased cortisol:DHEA(S) ratio. These changes may impair immune function, delay recovery, and exacerbate vulnerability to treatment toxicity. This narrative review synthesizes mechanistic and clinical evidence linking HPA-axis dysregulation to treatment tolerance in geriatric oncology. Common patterns include blunted diurnal cortisol slopes, elevated evening cortisol, and low DHEA(S), which are associated with fatigue, functional decline, and reduced survival across cancer types. However, their predictive value for acute treatment toxicities remains underexplored due to methodological heterogeneity, lack of age-specific reference ranges, and absence from existing geriatric toxicity models. This review proposes a translational roadmap that prioritizes (1) standardization of salivary cortisol/DHEA(S) protocols; (2) prospective, age-stratified validation studies using standardized toxicity endpoints; (3) interventional testing of behavioral or pharmacological strategies to modulate HPA function; and (4) integration into oncology workflows and electronic decision-support tools. Incorporating endocrine biomarkers into risk prediction could refine treatment stratification, enable targeted supportive care, and ultimately improve outcomes for older patients with cancer.
- 8 January 2026
- Published by MDPI AG in Preprints.org
Open AccessA Literature Review on Hypothalamic–Pituitary–Adrenal (HPA) Axis Dysregulation in Older Adults with Cancer: A Missing Link in Predicting Treatment Toxicity?
Older adults with cancer face disproportionately high rates of severe treatment-related toxicities, yet current prediction tools rarely incorporate biomarkers that capture physiological resilience. The hypothalamic–pituitary–adrenal (HPA) axis—central to stress adaptation, immune regulation, and tissue repair—undergoes pronounced age-related alterations, including elevated basal cortisol, reduced dehydroepiandrosterone (DHEA) and its sulphate form DHEAS, and an increased cortisol:DHEA(S) ratio. These changes may impair immune function, delay recovery, and exacerbate vulnerability to treatment toxicity. This narrative review synthesizes mechanistic and clinical evidence linking HPA-axis dysregulation to treatment tolerance in geriatric oncology. Common patterns include blunted diurnal cortisol slopes, elevated evening cortisol, and low DHEA(S), which are associated with fatigue, functional decline, and reduced survival across cancer types. However, their predictive value for acute treatment toxicities remains underexplored due to methodological heterogeneity, lack of age-specific reference ranges, and absence from existing geriatric toxicity models. This review proposes a translational roadmap that prioritizes (1) standardization of salivary cortisol/DHEA(S) protocols; (2) prospective, age-stratified validation studies using standardized toxicity endpoints; (3) interventional testing of behavioral or pharmacological strategies to modulate HPA function; and (4) integration into oncology workflows and electronic decision-support tools. Incorporating endocrine biomarkers into risk prediction could refine treatment stratification, enable targeted supportive care, and ultimately improve outcomes for older patients with cancer.
- Open Access
Synergy of Body Composition, Exercise Oncology, and Pharmacokinetics: A Narrative Review of Personalizing Paclitaxel Treatment for Breast Cancer
Background/Objectives: Paclitaxel is a type of small molecule chemotherapy widely used for breast cancer, but its clinical efficacy is often hindered by dose-limiting toxicities such as chemotherapy-induced peripheral neuropathy and neutropenia. Traditional dosing based on body surface area does not account for variations in body composition, which may influence paclitaxel metabolism, toxicity, and treatment outcomes. This review explores the interplay between body composition, physical activity, and paclitaxel pharmacokinetics, emphasizing the potential for personalized dosing strategies. Methods: A comprehensive narrative review was conducted by analyzing the literature on body composition, small molecule chemotherapy-related toxicities, pharmacokinetics, and exercise oncology. Studies examining the role of skeletal muscle mass, adipose tissue, and physical activity in modulating paclitaxel metabolism and side effects were included. Results: Evidence suggests that patients with low skeletal muscle mass are at a higher risk of paclitaxel-induced toxicities due to altered drug distribution and clearance. Sarcopenic obesity, characterized by low muscle and high-fat levels, further exacerbates these risks. Exercise, particularly resistance and aerobic training, has been shown to improve muscle mass, mitigate toxicities, and enhance chemotherapy tolerance. However, the precise mechanisms by which exercise influences paclitaxel pharmacokinetics remain underexplored. Conclusions: Personalized chemotherapy dosing, considering body composition and physical activity, may optimize paclitaxel treatment outcomes. Future research should focus on integrating exercise interventions into oncology care and refining dosing models that account for interindividual differences in drug metabolism. These advancements could improve treatment efficacy while minimizing toxicities in breast cancer patients.
Open AccessSynergy of Body Composition, Exercise Oncology, and Pharmacokinetics: A Narrative Review of Personalizing Paclitaxel Treatment for Breast Cancer
Background/Objectives: Paclitaxel is a type of small molecule chemotherapy widely used for breast cancer, but its clinical efficacy is often hindered by dose-limiting toxicities such as chemotherapy-induced peripheral neuropathy and neutropenia. Traditional dosing based on body surface area does not account for variations in body composition, which may influence paclitaxel metabolism, toxicity, and treatment outcomes. This review explores the interplay between body composition, physical activity, and paclitaxel pharmacokinetics, emphasizing the potential for personalized dosing strategies. Methods: A comprehensive narrative review was conducted by analyzing the literature on body composition, small molecule chemotherapy-related toxicities, pharmacokinetics, and exercise oncology. Studies examining the role of skeletal muscle mass, adipose tissue, and physical activity in modulating paclitaxel metabolism and side effects were included. Results: Evidence suggests that patients with low skeletal muscle mass are at a higher risk of paclitaxel-induced toxicities due to altered drug distribution and clearance. Sarcopenic obesity, characterized by low muscle and high-fat levels, further exacerbates these risks. Exercise, particularly resistance and aerobic training, has been shown to improve muscle mass, mitigate toxicities, and enhance chemotherapy tolerance. However, the precise mechanisms by which exercise influences paclitaxel pharmacokinetics remain underexplored. Conclusions: Personalized chemotherapy dosing, considering body composition and physical activity, may optimize paclitaxel treatment outcomes. Future research should focus on integrating exercise interventions into oncology care and refining dosing models that account for interindividual differences in drug metabolism. These advancements could improve treatment efficacy while minimizing toxicities in breast cancer patients.
- Open Access
- 4 March 2025
- Published by MDPI AG in Preprints.org
Synergy of Body Composition, Exercise Oncology and Pharmacokinetics: A Narrative Review in Personalizing Paclitaxel Treatment for Breast Cancer
Background/Objectives: Paclitaxel is a widely used type of chemotherapy for breast cancer, but its clinical efficacy is often hindered by dose-limiting toxicities such as chemotherapy-induced peripheral neuropathy and neutropenia. Traditional dosing based on body surface area does not account for variations in body composition, which may influence paclitaxel metabolism, toxicity, and treatment outcomes. This review explores the interplay between body composition, physical activity, and paclitaxel pharmacokinetics, emphasizing the potential for personalized dosing strategies. Methods: A comprehensive narrative review was conducted by analyzing literature on body composition, chemotherapy-related toxicities, pharmacokinetics, and exercise oncology. Studies examining the role of skeletal muscle mass, adipose tissue, and physical activity in modulating paclitaxel metabolism and side effects were included. Results: Evidence suggests that patients with low skeletal muscle mass are at a higher risk of paclitaxel-induced toxicities due to altered drug distribution and clearance. Sarcopenic obesity, characterized by low muscle and high-fat levels, further exacerbates these risks. Exercise, particularly resistance and aerobic training, has been shown to improve muscle mass, mitigate toxicities, and enhance chemotherapy tolerance. However, the precise mechanisms by which exercise influences paclitaxel pharmacokinetics remain underexplored Conclusions: Personalized chemotherapy dosing, considering body composition and physical activity, may optimize paclitaxel treatment outcomes. Future research should focus on integrating exercise interventions into oncology care and refining dosing models that account for interindividual differences in drug metabolism. These advancements could improve treatment efficacy while minimizing toxicities in breast cancer patients.
- 4 March 2025
- Published by MDPI AG in Preprints.org
Open AccessSynergy of Body Composition, Exercise Oncology and Pharmacokinetics: A Narrative Review in Personalizing Paclitaxel Treatment for Breast Cancer
Background/Objectives: Paclitaxel is a widely used type of chemotherapy for breast cancer, but its clinical efficacy is often hindered by dose-limiting toxicities such as chemotherapy-induced peripheral neuropathy and neutropenia. Traditional dosing based on body surface area does not account for variations in body composition, which may influence paclitaxel metabolism, toxicity, and treatment outcomes. This review explores the interplay between body composition, physical activity, and paclitaxel pharmacokinetics, emphasizing the potential for personalized dosing strategies. Methods: A comprehensive narrative review was conducted by analyzing literature on body composition, chemotherapy-related toxicities, pharmacokinetics, and exercise oncology. Studies examining the role of skeletal muscle mass, adipose tissue, and physical activity in modulating paclitaxel metabolism and side effects were included. Results: Evidence suggests that patients with low skeletal muscle mass are at a higher risk of paclitaxel-induced toxicities due to altered drug distribution and clearance. Sarcopenic obesity, characterized by low muscle and high-fat levels, further exacerbates these risks. Exercise, particularly resistance and aerobic training, has been shown to improve muscle mass, mitigate toxicities, and enhance chemotherapy tolerance. However, the precise mechanisms by which exercise influences paclitaxel pharmacokinetics remain underexplored Conclusions: Personalized chemotherapy dosing, considering body composition and physical activity, may optimize paclitaxel treatment outcomes. Future research should focus on integrating exercise interventions into oncology care and refining dosing models that account for interindividual differences in drug metabolism. These advancements could improve treatment efficacy while minimizing toxicities in breast cancer patients.
- Open Access
Dose-Limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition—A Protocol for an Observational Cohort Study
Background/Objectives: Paclitaxel (PTX), a commonly used chemotherapy for breast cancer (BC), is associated with dose-limiting toxicities (DLTs) such as peripheral neuropathy and neutropenia. These toxicities frequently lead to dose reductions, treatment delays, or therapy discontinuation, negatively affecting patients’ quality of life and clinical outcomes. Current dosing strategies based on body surface area (BSA) fail to account for individual variations in body composition (skeletal muscle mass (SMM) and adipose tissue (AT) mass) and physical activity (PA), which can influence drug metabolism and toxicity. This study aims to explore the relationships between PTX pharmacokinetics, body composition, and PA to predict DLTs. Methods: This single-group observational cohort study will recruit 40 female BC patients undergoing PTX treatment. Data collection will include plasma PTX concentrations, body composition assessments (using dual X-ray absorptiometry and bioelectrical impedance analysis), PA measurements (via accelerometers), and questionnaires to assess BC-related health-related quality of life, chemotherapy-induced peripheral neuropathy, and neutropenia during the PTX schedule using validated questionnaires. Dose-limiting toxicities will be graded according to the Common Terminology Criteria for Adverse Events v5.0 (grade 3 or higher). This protocol is designed to develop a population-based PK-PD model that predicts the occurrence of chemotherapy-induced peripheral neuropathy and neutropenia in women with stage II or III BC undergoing PTX therapy, focusing on explanatory outcomes related to SMM, AT mass, and PA.
Open AccessDose-Limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition—A Protocol for an Observational Cohort Study
Background/Objectives: Paclitaxel (PTX), a commonly used chemotherapy for breast cancer (BC), is associated with dose-limiting toxicities (DLTs) such as peripheral neuropathy and neutropenia. These toxicities frequently lead to dose reductions, treatment delays, or therapy discontinuation, negatively affecting patients’ quality of life and clinical outcomes. Current dosing strategies based on body surface area (BSA) fail to account for individual variations in body composition (skeletal muscle mass (SMM) and adipose tissue (AT) mass) and physical activity (PA), which can influence drug metabolism and toxicity. This study aims to explore the relationships between PTX pharmacokinetics, body composition, and PA to predict DLTs. Methods: This single-group observational cohort study will recruit 40 female BC patients undergoing PTX treatment. Data collection will include plasma PTX concentrations, body composition assessments (using dual X-ray absorptiometry and bioelectrical impedance analysis), PA measurements (via accelerometers), and questionnaires to assess BC-related health-related quality of life, chemotherapy-induced peripheral neuropathy, and neutropenia during the PTX schedule using validated questionnaires. Dose-limiting toxicities will be graded according to the Common Terminology Criteria for Adverse Events v5.0 (grade 3 or higher). This protocol is designed to develop a population-based PK-PD model that predicts the occurrence of chemotherapy-induced peripheral neuropathy and neutropenia in women with stage II or III BC undergoing PTX therapy, focusing on explanatory outcomes related to SMM, AT mass, and PA.
- Open Access
Recommended Physiotherapy Modalities for Oncology Patients with Palliative Needs and Its Influence on Patient-Reported Outcome Measures: A Systematic Review
Background: This review aims to explore the role of physiotherapy in early and traditional palliative care (PC) for oncology patients, focusing on its impact on six patient-reported outcomes (PROMs), namely fatigue, pain, cachexia, quality of life (QoL), physical functioning (PHF), and psychosocial functioning (PSF). The purpose is to assess the effectiveness of various physiotherapy interventions and identify gaps in the current research to understand their potential benefits in PC better. Methods: A systematic literature search was conducted across PubMed, Embase, and Web of Science, concluding on 21 December 2023. Two independent reviewers screened the articles for inclusion. The Cochrane Risk of Bias Tool 2 was employed to assess the risk of bias, while the GRADE approach was used to evaluate the certainty of the evidence. Results: Nine randomized controlled trials (RCTs) were included, with most showing a high risk of bias, particularly in outcome measurement and missing data. Cognitive behavioral therapy (CBT) was the only intervention that significantly reduced fatigue, enhanced PHF, and improved QoL and emotional functioning. Graded exercise therapy (GET) did not yield significant results. Combined interventions, such as education with problem-solving or nutritional counseling with physical activity, showed no significant effects. Massage significantly improved QoL and reduced pain, while physical application therapies were effective in pain reduction. Mindful breathing exercises (MBE) improved QoL but had a non-significant impact on appetite. The overall certainty of the evidence was low. Conclusions: Physiotherapy can positively influence PROMs in oncology PC; however, the low quality and high risk of bias in existing studies highlight the need for more rigorous research to confirm these findings and guide clinical practice.
Open AccessRecommended Physiotherapy Modalities for Oncology Patients with Palliative Needs and Its Influence on Patient-Reported Outcome Measures: A Systematic Review
Background: This review aims to explore the role of physiotherapy in early and traditional palliative care (PC) for oncology patients, focusing on its impact on six patient-reported outcomes (PROMs), namely fatigue, pain, cachexia, quality of life (QoL), physical functioning (PHF), and psychosocial functioning (PSF). The purpose is to assess the effectiveness of various physiotherapy interventions and identify gaps in the current research to understand their potential benefits in PC better. Methods: A systematic literature search was conducted across PubMed, Embase, and Web of Science, concluding on 21 December 2023. Two independent reviewers screened the articles for inclusion. The Cochrane Risk of Bias Tool 2 was employed to assess the risk of bias, while the GRADE approach was used to evaluate the certainty of the evidence. Results: Nine randomized controlled trials (RCTs) were included, with most showing a high risk of bias, particularly in outcome measurement and missing data. Cognitive behavioral therapy (CBT) was the only intervention that significantly reduced fatigue, enhanced PHF, and improved QoL and emotional functioning. Graded exercise therapy (GET) did not yield significant results. Combined interventions, such as education with problem-solving or nutritional counseling with physical activity, showed no significant effects. Massage significantly improved QoL and reduced pain, while physical application therapies were effective in pain reduction. Mindful breathing exercises (MBE) improved QoL but had a non-significant impact on appetite. The overall certainty of the evidence was low. Conclusions: Physiotherapy can positively influence PROMs in oncology PC; however, the low quality and high risk of bias in existing studies highlight the need for more rigorous research to confirm these findings and guide clinical practice.
- Open Access
- 10 September 2024
- Published by Elsevier in International Journal of Osteopathic Medicine
- Vol. 54
Osteopathic manual treatment in women with endometriosis: A scoping review on clinical symptoms, fertility and quality of life
- 10 September 2024
- Published by Elsevier in International Journal of Osteopathic Medicine
- Vol. 54
Open AccessOsteopathic manual treatment in women with endometriosis: A scoping review on clinical symptoms, fertility and quality of life
- Open Access
- 1 August 2023
- Published by Human Kinetics in Journal of Aging and Physical Activity
- Vol. 31 (4) , 679-692
Dimensions of Physical Activity Are Important in Managing Anxiety in Older Adults: A Systematic Review and Meta-Analysis
Physical activity (PA) is a known approach for managing anxiety symptoms in older adults. This systematic review and meta-analysis address the benefits of PA and its dimensions (frequency, session time, type, and intervention period) on anxiety symptoms in older adults aged 65 years and above. Searches covered eight databases reporting eight randomized controlled trials (RCTs) and five non-RCTs. Meta-analysis of RCTs (standardized mean difference = −0.41; 95% confidence interval [−0.58, −0.24]; p < .00001) and Fisher’s method of combining p values for non-RCTs supported the effectiveness of PA for managing anxiety symptoms in older adults. Subgroup analysis revealed significant effects for all PA types, session times, frequency, and intervention periods compared with control groups, albeit with different magnitudes of effect. In conclusion, although some dimensions of PA contribute to its effectiveness for anxiety, PA intensity and mode required to maximize PA effects remain unclear.
- 1 August 2023
- Published by Human Kinetics in Journal of Aging and Physical Activity
- Vol. 31 (4) , 679-692
Open AccessDimensions of Physical Activity Are Important in Managing Anxiety in Older Adults: A Systematic Review and Meta-Analysis
Physical activity (PA) is a known approach for managing anxiety symptoms in older adults. This systematic review and meta-analysis address the benefits of PA and its dimensions (frequency, session time, type, and intervention period) on anxiety symptoms in older adults aged 65 years and above. Searches covered eight databases reporting eight randomized controlled trials (RCTs) and five non-RCTs. Meta-analysis of RCTs (standardized mean difference = −0.41; 95% confidence interval [−0.58, −0.24]; p < .00001) and Fisher’s method of combining p values for non-RCTs supported the effectiveness of PA for managing anxiety symptoms in older adults. Subgroup analysis revealed significant effects for all PA types, session times, frequency, and intervention periods compared with control groups, albeit with different magnitudes of effect. In conclusion, although some dimensions of PA contribute to its effectiveness for anxiety, PA intensity and mode required to maximize PA effects remain unclear.